Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | Mar 8, 2019 at 10:05 AM EST

Can Tonix Regain Its Former Glory With New Neurodegenerative Dysfunction Drug?

Tonix Pharma shares spiked on Friday after the firm announced that it received a patent from the European Patent Office…

Chris Lange | Mar 7, 2019 at 1:15 PM EST

Bio-Path Shares on the Warpath

Bio-Path shares are on a rampage, with its second day of more than doubling. Shares actually were halted at multiple…

Paul Ausick | Mar 7, 2019 at 12:00 PM EST

How Soon Will Robots Replace Doctors?

Artificial intelligence and robots are poised to play a bigger role in medicine and health care. Will robots replace doctors?…

Chris Lange | Mar 6, 2019 at 1:40 PM EST

Why Bio-Path Shares Nearly Tripled

Bio-Path shares made an incredible run on Wednesday after the company announced interim results from its mid-stage leukemia trial.

Jon C. Ogg | Mar 6, 2019 at 6:35 AM EST

How Intercept Pharma Shares Could See Blockbuster Drug and See Its Shares Double

Intercept Pharmaceuticals was last seen trading higher after the company's financial reporting. While numbers are always important to see, a…

Chris Lange | Mar 4, 2019 at 9:50 AM EST

Why Ascendis Pharma Shares Hit an All-Time High

Ascendis Pharma shares spiked early Monday as the result of positive top-line results from its late-stage growth hormone study in…

Chris Lange | Mar 4, 2019 at 8:30 AM EST

Are Nightstar Shareholders Getting Enough in the Buyout?

Nightstar Therapeutics shares exploded early on Monday after it was announced that the firm would be acquired by Biogen. The…

Chris Lange | Mar 2, 2019 at 8:45 AM EST

Wedbush’s Top Biotech Picks Ahead of AACR Annual Meeting

Abstracts have been released for the companies presenting at the American Association for Cancer Research annual meeting, and Wedbush has…

Chris Lange | Mar 1, 2019 at 11:30 AM EST

What Lexicon Pharma Could Mean for the Future of Diabetes

Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive…

Chris Lange | Mar 1, 2019 at 10:15 AM EST

Is Immunogen Done After This Ovarian Cancer Study?

ImmunoGen shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.

Douglas A. McIntyre | Mar 1, 2019 at 6:30 AM EST

Fast Food Much Less Healthy Than 3 Decades Ago

Fast food is usually characterized as unhealthy, with high amounts of fat, salt and sugar. A new study shows that…

Chris Lange | Feb 28, 2019 at 11:35 AM EST

What’s Next for Horizon Pharma After This Late-Stage TED Trial

Horizon Pharma shares exploded on Thursday after the firm announced results from its late-stage trial evaluating teprotumumab for the treatment…

Chris Lange | Feb 28, 2019 at 8:35 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data…

Chris Lange | Feb 28, 2019 at 8:30 AM EST

Major Pharma Sees Tremendous Rise in Short Interest

The February 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Feb 27, 2019 at 11:25 AM EST

Why Tandem Diabetes Shares Are Soaring

Tandem Diabetes shares soared after it reported better-than-expected quarterly results and announced management changes.

1 … 104 105 106 107 108 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Can Tonix Regain Its Former Glory With New Neurodegenerative Dysfunction Drug?

Bio-Path Shares on the Warpath

How Soon Will Robots Replace Doctors?

Why Bio-Path Shares Nearly Tripled

How Intercept Pharma Shares Could See Blockbuster Drug and See Its Shares Double

Why Ascendis Pharma Shares Hit an All-Time High

Are Nightstar Shareholders Getting Enough in the Buyout?

Wedbush’s Top Biotech Picks Ahead of AACR Annual Meeting

What Lexicon Pharma Could Mean for the Future of Diabetes

Is Immunogen Done After This Ovarian Cancer Study?

Fast Food Much Less Healthy Than 3 Decades Ago

What’s Next for Horizon Pharma After This Late-Stage TED Trial

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Major Pharma Sees Tremendous Rise in Short Interest

Why Tandem Diabetes Shares Are Soaring

‘You Bought Stupid Cars You Can’t Afford. You Didn’t Buy a Stupid House.’: Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

'You Bought Stupid Cars You Can't Afford. You Didn't Buy a Stupid House.': Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

‘You Bought Stupid Cars You Can’t Afford. You Didn’t Buy a Stupid House.’: Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

Health and Healthcare Articles

All Health and Healthcare Articles

Can Tonix Regain Its Former Glory With New Neurodegenerative Dysfunction Drug?

Bio-Path Shares on the Warpath

How Soon Will Robots Replace Doctors?

Why Bio-Path Shares Nearly Tripled

How Intercept Pharma Shares Could See Blockbuster Drug and See Its Shares Double

Why Ascendis Pharma Shares Hit an All-Time High

Are Nightstar Shareholders Getting Enough in the Buyout?

Wedbush’s Top Biotech Picks Ahead of AACR Annual Meeting

What Lexicon Pharma Could Mean for the Future of Diabetes

Is Immunogen Done After This Ovarian Cancer Study?

Fast Food Much Less Healthy Than 3 Decades Ago

What’s Next for Horizon Pharma After This Late-Stage TED Trial

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Major Pharma Sees Tremendous Rise in Short Interest

Why Tandem Diabetes Shares Are Soaring

‘You Bought Stupid Cars You Can’t Afford. You Didn’t Buy a Stupid House.’: Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

Featured Reads

'You Bought Stupid Cars You Can't Afford. You Didn't Buy a Stupid House.': Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500